coronary artery disease [3] or hypertension [4]. As both With great interest we have read the publication by estrogens and ACE-I have been suggested to increase nitric Stork et al. [1] showing that hormone replacement therapy oxide (NO) production, it will be interesting to see (HRT) decreased plasma levels of monocyte chemotactic whether a synergistic effect can be observed between protein-1 (MCP-1) in humans: HRT lowered MCP-1 levels estrogens and ACE-I on MCP-1 plasma levels. by approximately 17% in hypercholesterolemic women with borderline hypertension after 12 months of therapy (treatment consisted of 1 mg / d estradiol plus 25 mg gestodene for 12 days either every month or every 3 R eferences months).
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